Last month, Santarus, Inc’s Uceris for ulcerative colitis received FDA approval, and the company has announced a planned launch in March 2013. Santaurs has already begun adding 85 new positions to its sales staff in anticipation of Uceris’ future. The Uceris approval hopes to promise strong returns for a company with a checkered past, but a promising future.
Aside from re-defined financing structures, the most important issue facing life sciences EGCs is the need to increase clinical trial efficiency and productivity so that development budgets are used prudently to support products that have the best chance of market success. Speaking to OneMedTV during OneMedForum this past January, Donnelly discussed current changes that will impact the future of product development and the central role that innovative trial design will play in this.
“On my second trip to Uganda in 2005 I operated on a 15-year-old girl who had fallen out of a mango tree and broke her neck. She was essentially a paraplegic,” recalls Dr. Isador “Izzy” Lieberman, a spine surgeon with Texas Back Institute.
Response Biomedical Corp. (RBM.TO)(RPBIF) is bringing in 2013 with a bang announcing their 2nd US distribution deal since the 1st week in January. Earlier in the month Response Biomedical entered a distribution agreement with US hospital supplier Laboratory Supply Company Inc. (Labsco) to distribute its cardiovascular portfolio of RAMP® products to small hospitals. By the end of January Response Biomedical announced their 2nd US distribution agreement with Fishers Healthcare for their RAMP® Flu A + B tests and RAMP® RSV test on the RAMP® 200.
Vascular Nanotransfer Technologies (VNT) says it has developed the industry’s most versatile Drug-Coated-Balloon (DCB) platform designed to deliver a wide variety of drugs for best-in-class DCB applications.
Every 21 seconds, someone suffers a serious brain injury, such as a stroke, which is the third-leading cause of death in the United States and the leading cause of long-term disability. Today, Jan Medical is on the cusp of commercializing its first application of a revolutionary system, Nautilus NeurowaveTM, designed to help doctors quickly identify vasospasm and strokes.
ADVENTRX (NYSE: ANX), a San Diego-based biopharmaceutical company, has made some strides in the development of a product candidate designed to treat genetic hematoma disorders, specifically sickle cell anemia (SCA), an orphan drug market with implications for millions of people.
Privately held CardioLogical Solutions is an emerging cardiovascular company formed this month by the merger of Emboline and VasoStitch. The company is developing a comprehensive suite of technologies that address the three biggest, and most pressing, clinical needs in order to make transcatheter aortic valve replacement (TAVR) procedures truly percutaneous and safer.
BOTHELL, WA—January 8, 2013—BioLife Solutions (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells […]
SpineGuard, based in San Francisco and Paris, is addressing a major unmet need in spine surgery: the safe placement of pedicle screws for both patients and OR personnel. PediGuard®, its core technology, is the world’s first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches during pedicle screw site preparation.
Copyright © 2024 | WordPress Theme by MH Themes